b) an inert carrier; and

c) a permeation enhancer selected from the group consisting of: fatty acids, fatty acid esters, fatty alcohols, amides, amines, pyrrolidones, terpenes, surfactants, complexing agents, L-α-amino acids, lecithin, phospholipids, their salts, and mixtures thereof.

6. (Once Amended) A transdermal formulation as set forth in claim 1, wherein the huperzine is a member selected from the group consisting of huperzine A, huperzine B, huperzine X, and salts, analogs, derivatives, prodrugs, and mixtures thereof.

Please add the following new Claims 51 and 52:

51. (New) A transdermal formulation as set forth in claim 1, wherein the fatty acid ester is a fatty acid ester of lactic acid, a fatty acid esters of glycolic acid, or a mixture thereof.

52. (New) A transdermal formulation as set forth in claim 1, wherein the fatty acid ester is a glycerol triester.

REMARKS

Applicants thank the Examiner for consideration of the subject patent application. In the office action mailed December 18, 2002, Claims 1-28 were pending for consideration. Each of these claims was rejected under both 35 U.S.C. §§ 112, second paragraph, and 103. Each rejection will be addressed in turn below. By the present amendment, Claims 1 and 6 have been amended and new